Author:
Agrogiannis George,Alamanis Christos,Karatrasoglou Eleni A.,Kousournas Georgios,Lazaris Andreas C.,Spapis Vasileios,Thomopoulou Georgia-Eleni,Zouki Dionysia N.
Publisher
Springer International Publishing
Reference53 articles.
1. Babjuk M, Böhle A, Burger M et al (2017a) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461
2. Babjuk M, Burger M, Compérat E, et al (2017b) Non-muscle-invasive bladder cancer. In: European Association of Urology Guidelines. European Association of Urology. Available via
https://uroweb.org/guideline/renal-cell-carcinoma
. Accessed 05 July 2017
3. Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064):67–76
4. Bamias A, Aravantinos G, Deliveliotis C et al (2004) Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22:220–228
5. Bellmunt J, Théodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454–4461
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献